FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W51270299> ?p ?o ?g. }

• W51270299 endingPage "2021" @default.
• W51270299 startingPage "2021" @default.
• W51270299 abstract "2021 Background: Recurrent grade III-IV malignant gliomas have a dismal prognosis and effective salvage therapies are limited. Methods: From 4/05–2/06, a phase II trial was conducted at Duke University using bevacizumab and irinotecan in patients with recurrent malignant gliomas. 2 cohorts were enrolled that included 33 grade III and 35 grade IV patients. The first cohort received bevacizumab at 10mg/kg plus irinotecan (dose based on patient's anticonvulsant) every two weeks. The second cohort received bevacizumab at 15mg/kg every 21 days and irinotecan on days 1, 8, 22, and 29. Results: Overall response rates for both grade III and IV were 59% (grade III 61%, grade IV 57%). 6 month PFS and OS for grade III were 59% and 79% and for grade IV 43% and 74% respectively. In 12/07, we evaluated all patients enrolled in the trial to determine the 2 yr OS. From the 2 cohorts, 22% (15/68) of the patients are still alive (11 grade III, 4 grade IV). For the grade IV patients, the 2yr OS is 15%. All four of the grade IV patients completed 9 cycles of therapy. Two (2/4) progressed (8mo and 17mo) and both reinitiated bevacizumab and irinotecan with radiographic response. The other two have been progression free since the end of treatment (11mo and 18mo). Surprisingly, both of these patients had only partial resections at the time of diagnosis. For the grade III patients, the 2 yr OS is 33%. All but one patient has progressed; ranging from 1 to 14 months. 4 patients are currently on bevacizumab-based therapy. 1 on carboplatin, 2 on etoposide and 1 on bevacizumab alone for radiation necrosis. The remaining patients are on metronomic temozolomide (2), etoposide (1), and a phase I clinical trial (2). 2 patients are currently being followed off therapy. The one patient who did not progress only received a partial cycle on study and had to discontinue secondary to TTP and has been off treatment for the last 21 months. Conclusions: The combination of bevacizumab and irinotecan provides a clinically meaningful treatment option for patients with recurrent malignant gliomas. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech Genentech Genentech Genentech" @default.
• W51270299 created "2016-06-24" @default.
• W51270299 creator A5002201007 @default.
• W51270299 creator A5011590188 @default.
• W51270299 creator A5014505996 @default.
• W51270299 creator A5017088990 @default.
• W51270299 creator A5020491326 @default.
• W51270299 creator A5021296578 @default.
• W51270299 creator A5057371623 @default.
• W51270299 creator A5059965175 @default.
• W51270299 creator A5069314279 @default.
• W51270299 creator A5085537336 @default.
• W51270299 date "2008-05-20" @default.
• W51270299 modified "2023-10-15" @default.
• W51270299 title "Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas" @default.
• W51270299 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.2021" @default.
• W51270299 hasPublicationYear "2008" @default.
• W51270299 type Work @default.
• W51270299 sameAs 51270299 @default.
• W51270299 citedByCount "18" @default.
• W51270299 countsByYear W512702992019 @default.
• W51270299 crossrefType "journal-article" @default.
• W51270299 hasAuthorship W51270299A5002201007 @default.
• W51270299 hasAuthorship W51270299A5011590188 @default.
• W51270299 hasAuthorship W51270299A5014505996 @default.
• W51270299 hasAuthorship W51270299A5017088990 @default.
• W51270299 hasAuthorship W51270299A5020491326 @default.
• W51270299 hasAuthorship W51270299A5021296578 @default.
• W51270299 hasAuthorship W51270299A5057371623 @default.
• W51270299 hasAuthorship W51270299A5059965175 @default.
• W51270299 hasAuthorship W51270299A5069314279 @default.
• W51270299 hasAuthorship W51270299A5085537336 @default.
• W51270299 hasConcept C121608353 @default.
• W51270299 hasConcept C126322002 @default.
• W51270299 hasConcept C141071460 @default.
• W51270299 hasConcept C143998085 @default.
• W51270299 hasConcept C2776694085 @default.
• W51270299 hasConcept C2777802072 @default.
• W51270299 hasConcept C2778227246 @default.
• W51270299 hasConcept C2780259306 @default.
• W51270299 hasConcept C502942594 @default.
• W51270299 hasConcept C526805850 @default.
• W51270299 hasConcept C71924100 @default.
• W51270299 hasConcept C72563966 @default.
• W51270299 hasConcept C90924648 @default.
• W51270299 hasConceptScore W51270299C121608353 @default.
• W51270299 hasConceptScore W51270299C126322002 @default.
• W51270299 hasConceptScore W51270299C141071460 @default.
• W51270299 hasConceptScore W51270299C143998085 @default.
• W51270299 hasConceptScore W51270299C2776694085 @default.
• W51270299 hasConceptScore W51270299C2777802072 @default.
• W51270299 hasConceptScore W51270299C2778227246 @default.
• W51270299 hasConceptScore W51270299C2780259306 @default.
• W51270299 hasConceptScore W51270299C502942594 @default.
• W51270299 hasConceptScore W51270299C526805850 @default.
• W51270299 hasConceptScore W51270299C71924100 @default.
• W51270299 hasConceptScore W51270299C72563966 @default.
• W51270299 hasConceptScore W51270299C90924648 @default.
• W51270299 hasIssue "15_suppl" @default.
• W51270299 hasLocation W512702991 @default.
• W51270299 hasOpenAccess W51270299 @default.
• W51270299 hasPrimaryLocation W512702991 @default.
• W51270299 hasRelatedWork W1974029597 @default.
• W51270299 hasRelatedWork W1991332977 @default.
• W51270299 hasRelatedWork W2035875009 @default.
• W51270299 hasRelatedWork W2037400652 @default.
• W51270299 hasRelatedWork W2112875714 @default.
• W51270299 hasRelatedWork W2417717847 @default.
• W51270299 hasRelatedWork W2745803145 @default.
• W51270299 hasRelatedWork W2789731973 @default.
• W51270299 hasRelatedWork W3041018076 @default.
• W51270299 hasRelatedWork W3158211927 @default.
• W51270299 hasVolume "26" @default.
• W51270299 isParatext "false" @default.
• W51270299 isRetracted "false" @default.
• W51270299 magId "51270299" @default.
• W51270299 workType "article" @default.